Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel agents for managing dyslipidaemia.

J D Best1, A J Jenkins

  • 1University of Melbourne, Department of Medicine, St Vincent's Hospital Melbourne, Victoria 3065, Australia. jdbest@unimelb.edu.au

Expert Opinion on Investigational Drugs
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous subcutaneous insulin infusion: a local perspective.

Hong Kong medical journal = Xianggang yi xue za zhi·2023
Same author

Skin autofluorescence in people with type 1 diabetes and people without diabetes: An eight-decade cross-sectional study with evidence of accelerated aging and associations with complications.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Recommendations for promoting healthier lifestyles in postpartum women after gestational diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

GooD4Mum: A general practice-based quality improvement collaborative for diabetes prevention in women with previous gestational diabetes.

Primary care diabetes·2018
Same author

Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus.

Lupus·2018
Same author

Short-term glucose variability in adults with Type 1 diabetes does not differ between insulin pump and multiple daily injection users - a masked continuous glucose monitoring study in clinical practice.

Diabetes & metabolism·2018

Lowering low-density lipoprotein (LDL) cholesterol with statins reduces coronary heart disease (CHD) risk. Future treatments aim to address all lipid abnormalities, including low high-density lipoprotein (HDL) cholesterol, for comprehensive CHD prevention.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Metabolic Disorders

Background:

  • Elevated low-density lipoprotein (LDL) cholesterol is a significant predictor of coronary heart disease (CHD).
  • Statins (HMG-CoA reductase inhibitors) are widely used for primary and secondary prevention of CHD by lowering LDL cholesterol.
  • Treatment challenges persist regarding optimal LDL reduction and combination therapies for very high LDL levels.

Purpose of the Study:

  • To review current treatment issues and novel agent development for lipid management in CHD prevention.
  • To focus on patients with low high-density lipoprotein (HDL) cholesterol, often associated with hypertriglyceridaemia and insulin resistance.
  • To explore future strategies for comprehensive lipid abnormality correction beyond LDL lowering.

Main Methods:

Related Experiment Videos

  • Review of accumulated evidence on statin efficacy and treatment challenges.
  • Discussion of emerging therapeutic targets and drug classes for lipid modification.
  • Analysis of the link between metabolic syndrome components (insulin resistance, obesity, diabetes) and dyslipidaemia.

Main Results:

  • Statins effectively reduce CHD risk by lowering LDL cholesterol.
  • Novel agents are being developed to target low HDL cholesterol, including CETP inhibitors, RXR agonists, PPAR agonists, and estrogen-like compounds.
  • Agents targeting both cholesterol and triglycerides, such as MTP inhibitors and AMP kinase agonists, are under investigation.

Conclusions:

  • Future CHD prevention strategies will emphasize correcting all lipid abnormalities, not solely focusing on LDL cholesterol reduction.
  • Addressing low HDL cholesterol and hypertriglyceridaemia is crucial, especially with rising rates of obesity, diabetes, and insulin resistance.
  • Combination therapies and novel agents offer promising avenues for comprehensive lipid management and cardiovascular risk reduction.